Novo Nordisk shares plunge after Alzheimer’s drug trial fails to hit key target
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the…
